Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C.

Blood. 2008 May 1;111(9):4681-9. doi: 10.1182/blood-2007-11-125278.

2.
3.

NF-kappaB dimers in the regulation of neuronal survival.

Sarnico I, Lanzillotta A, Benarese M, Alghisi M, Baiguera C, Battistin L, Spano P, Pizzi M.

Int Rev Neurobiol. 2009;85:351-62. doi: 10.1016/S0074-7742(09)85024-1. Review.

PMID:
19607980
4.

NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.

Pepper C, Hewamana S, Brennan P, Fegan C.

Future Oncol. 2009 Sep;5(7):1027-37. doi: 10.2217/fon.09.72. Review.

PMID:
19792971
5.

Post-ischemic brain damage: NF-kappaB dimer heterogeneity as a molecular determinant of neuron vulnerability.

Pizzi M, Sarnico I, Lanzillotta A, Battistin L, Spano P.

FEBS J. 2009 Jan;276(1):27-35. doi: 10.1111/j.1742-4658.2008.06767.x. Review.

6.

NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases.

Lanzillotta A, Porrini V, Bellucci A, Benarese M, Branca C, Parrella E, Spano PF, Pizzi M.

Front Neurol. 2015 May 20;6:98. doi: 10.3389/fneur.2015.00098. Review.

7.

c-Rel in Epidermal Homeostasis: A Spotlight on c-Rel in Cell Cycle Regulation.

Lorenz VN, Schön MP, Seitz CS.

J Invest Dermatol. 2016 Jun;136(6):1090-6. doi: 10.1016/j.jid.2016.02.003. Review.

PMID:
27032306
Items per page

Supplemental Content

Support Center